Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

Income Statement

Follow revenue through to earnings.

Revenue

$59,000.00

FY 2025 · Annual

-86.6% YoY

Operating Income

-$72.92M

FY 2025 · Annual

Net Income

-$78.26M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.4M18.05M1.92M441K59K
Cost of Revenue1.49M3.43M1.28M(366K)0
Gross Profit3.91M14.62M640K807K59K
Gross Margin72.4%81.0%33.3%183.0%100.0%
Research & Development59.84M31.31M13.78M52.08M50.08M
Selling, General & Admin24.66M20.71M10.3M17.24M22.9M
Operating Expenses86.04M52.06M27.99M69.32M72.98M
Depreciation & Amortization1.66M166K158K169K344K
EBITDA(80.5M)(37.29M)(23.29M)(34.85M)(77.75M)
EBITDA Margin-1491.2%-206.6%-1210.3%-7901.6%-131779.7%
Operating Income(82.13M)(37.44M)(27.35M)(68.51M)(72.93M)
Operating Margin-1521.6%-207.4%-1421.6%-15535.6%-123601.7%
Interest Income0003.32M4.35M
Interest Expense2.39M4.17M3.42M00
Other Income / Expenses(2.41M)(4.19M)(4.18M)33.5M(5.17M)
Income Before Tax(84.55M)(41.63M)(31.53M)(35.02M)(78.09M)
Pre-Tax Margin-1566.2%-230.6%-1638.8%-7939.9%-132362.7%
Income Tax Expense(196K)28K14K114K165K
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Net Margin-1563.1%-230.8%-1639.5%-7965.8%-132642.4%
EPS (Basic)(2,330.66)(1,062.65)(113.58)(4.32)(5.84)
EPS (Diluted)(2,330.66)(1,062.65)(113.58)(3.26)(5.84)
Weighted Avg Shares36.19K39.2K277.73K8.13M13.4M
Weighted Avg Shares (Diluted)36.19K39.2K277.73K10.78M13.4M

AVTX Earnings Waterfall · TTM

NASDAQ:AVTX · Revenue to Net Income

Key Ratios

EPS$-5.83
Gross Margin25.0%
Net Margin-5813.6%
P/E Ratio-3.0
P/S Ratio1424.5

Analysis

$59.0K of revenue converted into -$84.7M of net income for the selected period. Gross margin is 25.0% and net margin is -5813.6%, showing how much revenue survives after costs and taxes. EPS is $-5.83, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
S-3ASRS-3ASR filingNov 5, 2026
SC 13G/ASC 13G/A filingNov 5, 2026

How much revenue does AVTX generate?

Avalo Therapeutics, Inc. (AVTX) reported $59,000.00 of revenue in fiscal 2025.

Is AVTX profitable?

Avalo Therapeutics, Inc. (AVTX) reported -$78.26M of net income, with a net margin of -132642.4%.